Modification of intracellular pH and thermosensitivity
- PMID: 1728060
Modification of intracellular pH and thermosensitivity
Abstract
The effects of amiloride (an inhibitor of Na+/H+ antiport), DIDS (an inhibitor of Na(+)-coupled and Na(+)-independent HCO3-/Cl- exchange) and nigericin (K+/H+ ionophore) alone and in various combinations on the intracellular pH (pHi) and thermosensitivity of SCK tumor cells were studied. Hyperthermia alone at 43 degrees C for 2 h decreased pHi of SCK cells by 0.15-0.20 pH units, as measured fluorometrically using the pH-sensitive dye BCECF. When the cells were treated with 0.5 mM amiloride at 37 degrees C, the pHi declined by 0.10-0.15 pH units at an extracellular pH (pHe) of both 7.2 and 6.6. Amiloride at 0.5 mM enhanced the thermal damage to SCK cells at pHe 6.6 but not at pHe 7.2. DIDS alone at 0.1 mM exerted no effect on pHi or cellular thermosensitivity. DIDS, however, enhanced the effects of amiloride in decreasing pHi and in increasing the thermoresponse of SCK cells, particularly at pHe 6.6. Treatment of the cells with nigericin at 0.1-1.0 micrograms/ml lowered the pHi and enhanced the thermosensitivity of the cells in a dose-dependent manner. Reductions in pHi and increases in thermosensitivity by nigericin at the lower concentration at pHe 6.6 were far greater than at pHe 7.2. When a mixture of 1.0 micrograms/ml nigericin, 0.5 mM amiloride, and 0.1 mM DIDS was present in the medium, the pHi rapidly decreased by about 0.3 and 0.4 pH units at pHe 7.2 and 6.6, respectively. This drug combination was also extremely effective in sensitizing SCK cells to heat, particularly at pHe 6.6. The fact that the thermosensitization by these drugs at pHe 6.6 is more pronounced than at pHe 7.2 and that intratumor environments are known to be acidic strongly suggested that it may then be possible to enhance the thermal damage with such drugs preferentially in tumors relative to normal tissues.
Similar articles
-
Cytotoxicity of compounds that interfere with the regulation of intracellular pH: a potential new class of anticancer drugs.Cancer Res. 1987 Mar 15;47(6):1497-504. Cancer Res. 1987. PMID: 3815351
-
Reduction of intracellular pH as a possible mechanism for killing cells in acidic regions of solid tumors: effects of carbonylcyanide-3-chlorophenylhydrazone.Cancer Res. 1989 Aug 15;49(16):4477-82. Cancer Res. 1989. PMID: 2743336
-
Thermosensitization by increasing intracellular acidity with amiloride and its analogs.Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1161-9. doi: 10.1016/0360-3016(94)90324-7. Int J Radiat Oncol Biol Phys. 1994. PMID: 7961026
-
Stimulus-secretion coupling in beta-cells: modulation by pH.Am J Physiol. 1983 Jan;244(1):E3-18. doi: 10.1152/ajpendo.1983.244.1.E3. Am J Physiol. 1983. PMID: 6295181 Review.
-
Role of pH as a transduction device in triggering electrical and secretory responses in islet B cells.Fed Proc. 1984 Jun;43(9):2379-84. Fed Proc. 1984. PMID: 6327397 Review.
Cited by
-
(31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan.NMR Biomed. 2013 Jan;26(1):98-105. doi: 10.1002/nbm.2824. Epub 2012 Jun 29. NMR Biomed. 2013. PMID: 22745015 Free PMC article.
-
Topiramate induces acute intracellular acidification in glioblastoma.J Neurooncol. 2016 Dec;130(3):465-472. doi: 10.1007/s11060-016-2258-y. Epub 2016 Sep 9. J Neurooncol. 2016. PMID: 27613534
-
Rapid increase in pH set-point of the Na(+)-in-dependent chloride/bicarbonate antiporter in Vero cells exposed to heat shock.J Membr Biol. 1993 Jun;134(2):143-53. doi: 10.1007/BF00232750. J Membr Biol. 1993. PMID: 8411117
-
Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours.Br J Cancer. 1993 Nov;68(5):890-7. doi: 10.1038/bjc.1993.451. Br J Cancer. 1993. PMID: 8217605 Free PMC article.
-
Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.J Neurooncol. 1998 Jan;36(2):149-57. doi: 10.1023/a:1005819604858. J Neurooncol. 1998. PMID: 9525814